Sermorelin: what it is for, its FDA history and what the research shows

Published November 12, 2026. Sources last read November 12, 2026. Information only, not medical advice. Ask a licensed clinician before you start or stop any treatment.

The short answer

Sermorelin is a lab-made version of growth hormone-releasing hormone (GHRH), the signal that tells the pituitary gland to release growth hormone. It is used to raise the body's own growth hormone. [4][6]

The FDA approved it under the brand Geref in 1990 and 1997. Its maker, EMD Serono, discontinued it in 2008, and in 2013 the FDA found it had not been withdrawn for reasons of safety or effectiveness. [1]

The published studies are few and small: a 1999 review of its use in children, a 1992 trial in 10 older men and a 2006 editorial. [4][5][6]

Sermorelin is not on any of the FDA's three 503A nomination lists, and the FDA does not review compounded drugs before they are sold. [7][9]

Cheapest sermorelin this week

Tied at $99 a month: CoreAge Rx, Embody, Lttl, Strut Health and Villas Health.

  1. CoreAge Rx logoCoreAge Rxfrom $99 a month, no membership fee. No long-term contractSermorelin injectionChecked November 21, 2026 on CoreAge Rx's own pageCheck price at CoreAge Rx →
  2. Embody logoEmbody$99 a month, after a $49 first monthSermorelin injectionChecked November 21, 2026 on Embody's own pageCheck price at Embody →
  3. Lttl logoLttlfrom $99 a month, visits included. The plan is set at checkoutSermorelin injectionChecked November 21, 2026 on Lttl's own pageCheck price at Lttl →
  4. Strut Health logoStrut Health$99 a month, on auto-refillSermorelin lozengeChecked November 21, 2026 on Strut Health's own pageCheck price at Strut Health →
  5. Villas Health logoVillas Health$99 a month, monthly subscription; $119 as a one-time purchaseSermorelin injectionChecked November 21, 2026 on Villas Health's own pageSee prices

Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money

Prices checked by The Pep Chart on , from each program's own page. How we check prices | How we make money

Programs pay us when you sign up through our links. Affiliate disclosure

Every Sermorelin price we track, cheapest first: the Sermorelin price chart.

What sermorelin is for

Sermorelin binds receptors on the pituitary gland and raises the body's own growth hormone release, rather than adding growth hormone from outside. Its effect is held in check by somatostatin, the hormone that slows growth hormone release. [6]

The FDA approved Geref for two uses: as a test of whether the pituitary gland can release growth hormone, and to treat idiopathic growth hormone deficiency in children with growth failure. [1]

A 2006 editorial argues for sermorelin in adults whose growth hormone falls with age (adult-onset growth hormone insufficiency), and calls for studies to test that use. [6]

Its FDA history

The FDA first approved Geref (sermorelin acetate) 0.05 mg ampules on December 28, 1990, under NDA 19-863. It approved 0.5 mg and 1.0 mg vials on September 26, 1997, under NDA 20-443. EMD Serono held both. [1][2][3]

Those approvals covered the diagnostic ampule and the vials for children with growth failure described above. [1]

EMD Serono told the FDA in July 2008 that it was discontinuing the ampule and in December 2008 that it was discontinuing the vials. The FDA withdrew approval of both applications effective June 18, 2009. [1]

After a citizen petition in 2012, the FDA ruled in a March 4, 2013 notice that Geref was not withdrawn from sale for reasons of safety or effectiveness. [1]

Drugs@FDA lists every Geref strength as discontinued, and a DailyMed search for sermorelin returns no drug labels. [2][3][10]

What the research shows

A 1999 review found limited data that nightly sermorelin worked in some prepubertal children with idiopathic growth hormone deficiency. Their gains in growth rate were smaller than in children given somatropin, though the two were not compared head to head, and the effect on final adult height was not known. [4]

In adults, a 1992 trial gave a lab-made GHRH fragment to 10 healthy men aged about 68 for two 14-day periods at two strengths. The higher strength raised their 24-hour growth hormone and IGF-I levels. The authors wrote that longer treatment might improve body composition, which the trial did not test. [5]

The 2006 paper often cited for adult use is a two-page editorial, not a trial. [6]

We found no FDA label for sermorelin today. Drugs@FDA does not host the Geref label and DailyMed lists none. [3][10]

Forms

The FDA listed Geref only as an injection. The 1999 review describes an IV test and a nightly injection under the skin. [3][4]

Side effects in the studies

The 1999 review names brief facial flushing and pain at the injection site as the most common side effects. [4]

In the 1992 trial of older men, fasting glucose, blood pressure and routine blood tests did not change. [5]

Compounded sermorelin today

Sermorelin is not on any of the FDA's three 503A nomination lists, updated May 14, 2026. [7]

The FDA says a 503A pharmacy may compound only with a bulk substance that meets a USP or NF monograph, is a component of an FDA-approved drug or is on the 503A bulks list. [8]

The FDA says it does not check compounded drugs for safety, effectiveness or quality before they are sold, and that they are meant for patients whose needs an approved drug cannot meet. [9]

Sources

  1. Determination that GEREF (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness, 78 FR 14095, FDA, Federal Register, 2013-03-04. Read November 12, 2026. Our saved copy.
  2. Drugs@FDA: NDA 019863, GEREF, FDA. Read November 12, 2026. Our saved copy.
  3. Drugs@FDA: NDA 020443, GEREF, FDA. Read November 12, 2026. Our saved copy.
  4. Prakash and Goa, review of sermorelin in children (BioDrugs 12(2):139-57), BioDrugs, via PubMed, 1999-08. Read November 12, 2026. Our saved copy.
  5. Corpas and others, trial of GHRH-(1-29) in old men (J Clin Endocrinol Metab 75:530-5), Journal of Clinical Endocrinology and Metabolism, via PubMed, 1992-08. Read November 12, 2026. Our saved copy.
  6. Walker, editorial on sermorelin (Clinical Interventions in Aging 1(4):307-308), Clinical Interventions in Aging, via PMC, 2006-12. Read November 12, 2026. Our saved copy.
  7. Bulk drug substances nominated for use in compounding under section 503A (categories 1, 2 and 3), FDA, 2026-05-14. Read November 12, 2026. Our saved copy.
  8. Bulk drug substances used in compounding under section 503A of the FD&C Act, FDA. Read November 12, 2026. Our saved copy.
  9. Compounding and the FDA: questions and answers, FDA. Read November 12, 2026. Our saved copy.
  10. DailyMed search for sermorelin, National Library of Medicine. Read November 12, 2026. Our saved copy.

How we check sources: editorial policy. Rules for compounded peptides: FDA status of every peptide we track.

Not medical advice.

FDA status

The brand Geref was approved and discontinued, not withdrawn for safety.

FDA status of every peptide we track